Gene · 155
ADRB3: adrenoceptor beta 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADRB3: adrenoceptor beta 3. Genes, record 155. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/155
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P13945 | Beta-3 adrenergic receptor | 408 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents60
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 36853 | P13945 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 6649 | P13945 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 338 | P13945 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 338 | P13945 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 6649 | P13945 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 3473 | P13945 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 3474 | P13945 | Espacenet |
| US 11673938 B2 | 2023-06-13 | 4 | P13945 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 3473 | P13945 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 3474 | P13945 | Espacenet |
1 to 10 of 60
See all 60 patentsDrugs33
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMIBEGRON | CHEMBL1193948 | Beta-3 adrenergic receptor agonist | AGONIST | ChEMBL |
| AMIBEGRON HYDROCHLORIDE | CHEMBL545437 | Beta-3 adrenergic receptor agonist | AGONIST | ChEMBL |
| CARTEOLOL | CHEMBL839 | Adrenergic receptor beta antagonist | ANTAGONIST | ChEMBL |
| CARTEOLOL HYDROCHLORIDE | CHEMBL1201002 | Adrenergic receptor beta antagonist | ANTAGONIST | ChEMBL |
| CARVEDILOL | CHEMBL723 | Adrenergic receptor beta antagonist | ANTAGONIST | ChEMBL |
| CARVEDILOL PHOSPHATE | CHEMBL1201167 | Adrenergic receptor beta antagonist | ANTAGONIST | ChEMBL |
| DILEVALOL | CHEMBL27193 | Adrenergic receptor beta antagonist | ANTAGONIST | ChEMBL |
| DILEVALOL HYDROCHLORIDE | CHEMBL1204165 | Adrenergic receptor beta antagonist | ANTAGONIST | ChEMBL |
| DIPIVEFRIN | CHEMBL1201262 | Adrenergic receptor agonist | AGONIST | ChEMBL |
| DIPIVEFRIN HYDROCHLORIDE | CHEMBL1200833 | Adrenergic receptor agonist | AGONIST | ChEMBL |
1 to 10 of 33
See all 33 drugsTrials522
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07577518 | CARVEDILOL | ClinicalTrials.gov | ||
| NCT07572656 | LABETALOL | ClinicalTrials.gov | ||
| NCT07566208 | MIRABEGRON | PHASE2 | ClinicalTrials.gov | |
| NCT07442643 | EPINEPHRINE | ClinicalTrials.gov | ||
| NCT07442071 | EPINEPHRINE | PHASE3 | ClinicalTrials.gov | |
| NCT07398508 | DROXIDOPA | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07364201 | LABETALOL | ClinicalTrials.gov | ||
| NCT07363343 | LABETALOL | ClinicalTrials.gov | ||
| NCT07350070 | CARVEDILOL | PHASE2 | ClinicalTrials.gov | |
| NCT07343206 | NOREPINEPHRINE | ClinicalTrials.gov |
1 to 10 of 522
See all 522 trialsNIH grants1,817
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADRB3 papers | Newest fiscal year |
|---|---|---|---|
| R01DK097441 | Molecular mechanisms of UCP1-independent pathways in metabolic health | 23 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 16 | 2025 |
| P30DK036836 | Diabetes Research Center | 16 | 2025 |
| P30DK026687 | New York Obesity Research Center | 11 | 2025 |
| R01DK062292 | Analysis of Cellular Plasticity in White Adipose Tissue. | 10 | 2025 |
| P30DK020541 | NYR-Diabetes Research Center (NYR-DRC) | 9 | 2025 |
| ZIADK075116 | Physiological Responses to Activation of Human Brown Adipose Tissue | 9 | 2025 |
| ZIADK075112 | The Molecular, Cellular, and Genetic characterization of Human Adipose Tissue and its Role in Metabolism | 8 | 2025 |
| ZIADK075115 | Mechanisms Underlying Adipose Tissue Thermogenesis | 8 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
1 to 10 of 1,817Source NIH's project files
See all 1,817 nih grantsPapers3,802
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Delayed late ventricular depolarization is associated with inflammation in epicardial Fat Among females: a New avenue in cardiac electrophysiology. | Front Cardiovasc Med | 2026 | 42769221 | PubTator, text mining | PubMed |
| ADRB3, LEPR, FTO and PPARG variants contribute to obesity-related metabolic syndrome in Brazilian adults: a polygenic risk score approach. | Int J Obes (Lond) | 2026 | 42768086 | PubTator, text mining | PubMed |
| Potential roles of β3-adrenergic receptor in heart rate regulation via sinus node activity and local adipocyte metabolism. | J Physiol Sci | 2026 | 42759187 | PubTator, text mining | PubMed |
| Comparative analysis of infarct-reducing properties of ß1 -, ß2 -, and ß3 -adrenergicreceptor ligands in ischemia and reperfusion of the heart. | Pharmacology | 2026 | 42743088 | PubTator, text mining | PubMed |
| Through beta2 or not through beta2-That's the question. | Cell Metab | 2026 | 42679789 | PubTator, text mining | PubMed |
| cAMP and cGMP pathways modulate spontaneous contractile activity in human seminal vesicle smooth muscle. | Auton Neurosci | 2026 | 42679515 | PubTator, text mining | PubMed |
| Sex-Specific Associations Between MTHFR, PPARG and ADRB3 Polymorphisms, Habitual Nutrient Intake and Metabolic Risk in Obesity: A Cross-Sectional Single-Centre Study. | Nutrients | 2026 | 42588145 | PubTator, text mining | PubMed |
| Beta2-adrenergic stimulation by fenoterol increases energy expenditure without activating human brown adipose tissue. | Cell Metab | 2026 | 42586060 | PubTator, text mining | PubMed |
| The impact of FTO and ADRB3 gene variants, physical activity and proper diet on weight gain and perinatal outcomes in pregnant women with obesity. | J Appl Genet | 2026 | 42552455 | PubTator, text mining | PubMed |
| Exploring β3-Adrenergic Receptor, HIF-1α, and CD31 Interplay in the Microenvironment of Atypical Melanocytic Lesions. | Dermatopathology (Basel) | 2026 | 42496237 | PubTator, text mining | PubMed |
1 to 10 of 3,802
See all 3,802 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/155
GET https://conductscience.org/api/genes/v1/155/patents?page=2